New research presented at the American Society of Clinical Oncology (ASCO) conference in Chicago highlights significant progress in cancer treatment through precision-targeted drugs and personalized therapies.One of the most discussed developments was an experimental drug, GRWD5769, designed to help the immune system recognize and attack cancer cells.

When combined with immunotherapy, it achieved tumor reductions of at least 30 percent across multiple cancer types, with 26 out of 83 patients showing meaningful improvement.Another promising advancement involves Darasxnorasib, a daily pill for pancreatic cancer patients.

In clinical trials involving 500 individuals, the drug nearly doubled average survival time compared to standard chemotherapy, increasing it from approximately 6.6 months to 13.2 months.Researchers described this as a major step forward for a disease known for its poor prognosis.

The OPTIMA trial, led by University College London, demonstrated how genetic testing can identify breast cancer patients who may safely avoid chemotherapy.Among 4,000 participants, low-risk individuals were successfully treated with hormone therapy alone.Similarly, new treatment combinations for bladder cancer are helping patients avoid invasive surgery.

Despite these encouraging results, experts warn that cancer rates are expected to rise significantly, from 165 cases per 100,000 people in 2025 to 200 by 2050.Annual diagnoses could increase from 20 million to over 35 million globally due to aging populations and demographic changes.Additional studies also highlighted lifestyle factors.

Chronic insomnia was linked to a higher risk of several cancers among younger adults, while practices such as yoga were shown to improve mental health and reduce fatigue in patients.

Overall, while targeted therapies are advancing rapidly, they are not yet a complete replacement for chemotherapy but represent an important shift toward more personalized cancer care.